Novartis AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
- Introduction
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
An Open, Randomized Pilot Study to Evaluate the Use of Basiliximab With an Optimized Cyclosporine Dosing on Renal Function in "de Novo" Liver Transplantation.
- Conditions
- Liver Transplantation
- First Posted Date
- 2006-06-22
- Last Posted Date
- 2010-08-25
- Lead Sponsor
- Novartis
- Target Recruit Count
- 48
- Registration Number
- NCT00343226
Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase
- Conditions
- Multiple Sclerosis
- Interventions
- First Posted Date
- 2006-06-21
- Last Posted Date
- 2017-09-21
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1292
- Registration Number
- NCT00340834
- Locations
- 🇺🇸
Associated Neurologists, PC, 69 Sand Pit Road, Suite 300, Danbury, Connecticut, United States
🇺🇸AMO Corporation, Tallahassee, Florida, United States
🇺🇸Neurological Associates, Pompano Beach, Florida, United States
Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Subjects 18 Years of Age or Older
- Conditions
- Influenza
- First Posted Date
- 2006-06-21
- Last Posted Date
- 2017-04-20
- Lead Sponsor
- Novartis
- Registration Number
- NCT00342940
- Locations
- 🇬🇧
Chiltern International Limited , Chiltern Place, Upton Road, Slough, United Kingdom
Long Term Study of VAH631 in Patients With Essential Hypertension (Extension From B1303 Study)
- Conditions
- Hypertension
- First Posted Date
- 2006-06-20
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 362
- Registration Number
- NCT00338936
EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer
- Conditions
- Neoplasms, Breast
- First Posted Date
- 2006-06-20
- Last Posted Date
- 2016-04-06
- Lead Sponsor
- Novartis
- Registration Number
- NCT00338247
- Locations
- 🇬🇧
Novartis Investigative Site, Shrewsbury, United Kingdom
Comparative Study of Valsartan and Amlodipine Versus Amlodipine Alone in Hypertension
- Conditions
- Hypertension
- First Posted Date
- 2006-06-05
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 551
- Registration Number
- NCT00333489
- Locations
- 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland
Efficacy and Safety of Lumiracoxib 400 mg in Arthroscopic Knee Surgery
- Conditions
- Pain
- First Posted Date
- 2006-06-05
- Last Posted Date
- 2007-12-13
- Lead Sponsor
- Novartis
- Target Recruit Count
- 110
- Registration Number
- NCT00333567
- Locations
- 🇩🇪
Novartis, Nuernberg, Germany
Safety/Efficacy of Letrozole Monotherapy or in Combination With Zoledronic Acid as Extended Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer
- Conditions
- OsteoporosisPostmenopausal
- Interventions
- First Posted Date
- 2006-06-02
- Last Posted Date
- 2011-11-16
- Lead Sponsor
- Novartis
- Target Recruit Count
- 83
- Registration Number
- NCT00332709
- Locations
- 🇩🇪
Novaertis Investigative Site, Hamein, Germany
🇩🇪Novartis Investigative Site, Witten, Germany
Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis
- First Posted Date
- 2006-06-02
- Last Posted Date
- 2017-09-15
- Lead Sponsor
- Novartis
- Target Recruit Count
- 281
- Registration Number
- NCT00333138
- Locations
- 🇬🇧
Novartis Investigational site, Newcastle upon Tyne, United Kingdom
Letrozole in Metastatic Breast Cancer in Combination With Chemotherapy
- Conditions
- Metastatic Breast Cancer
- First Posted Date
- 2006-06-02
- Last Posted Date
- 2009-11-19
- Lead Sponsor
- Novartis
- Target Recruit Count
- 24
- Registration Number
- NCT00333047